C2N Diagnostics has announced a $10m investment from a group of Samsung companies, including Samsung C&T, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment.
The funding will support C2N’s efforts to enhance its capabilities, ensuring that patients around the world gain access to its blood biomarker testing technologies for Alzheimer’s disease and related dementias.
Samsung C&T executive vice president Jaywoo Kim said: “Since Samsung C&T stepped into the life sciences industry by investing in biologics CDMO and biosimilar business, it has contributed to the stabilisation of the biopharmaceutical supply chain and better access to high quality bio pharmaceutics.
“The investment into C2N Diagnostics shows Samsung’s continued dedication to future growth in the Life Science sector by seeking new business opportunities based on intelligent analytics and uniquely special diagnostics technologies.
“We are confident that C2N Diagnostics will further grow its leading position in the industry by serving global biopharma customers as well as medical service providers with its well-established blood biomarker testing portfolio.”
C2N highlights the critical need for early and precise diagnosis due to the extensive personal, financial, and societal effects associated with Alzheimer’s disease.
A recent clinical study published in the Journal of the American Medical Association (JAMA) assessed the effectiveness of C2N’s PrecivityAD2 blood test algorithm in improving diagnostic accuracy for Alzheimer’s disease within primary care settings, where many patients seek initial evaluations for memory-related concerns.
The results indicated that the test demonstrated strong performance, achieving a statistically significant accuracy rate of over 90% at a specified binary cutoff when compared to cerebrospinal fluid (CSF) analysis and amyloid PET imaging.
C2N has reported more than 50,000 Precivity analytes and has established over 150 collaborations in neuro-related academic, clinical, and research fields globally, underscoring its impact on Alzheimer’s research.
The company is also working to expand its biomarker pipeline by developing advanced assays that focus on tau pathology and Parkinson’s disease research, alongside initiatives aimed at decentralising mass spectrometry testing.
C2N CEO Dr Joel Braunstein said: “We greatly appreciate the confidence Samsung brings to this partnership as we believe it affirms the value and quality of our advanced diagnostic solutions.
“Samsung’s important investment will allow C2N to further strengthen our capabilities, expand our commercial scale, and innovate next generation diagnostic tests that can improve patients’ lives.”
